Khiron Life Sciences completes acquisition of Pharmadrug Production GmbH

1 minute read
02 August 2022

On August 2, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) announced that it had completed its previously announced acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (CSE:PHRX) (OTC: LMLLF). 

Khiron is a leading vertically integrated international medical cannabis corporation with core operations in Latin America and Europe. This acquisition will provide Khiron with a European manufacturing and distribution hub for medical cannabis and other pharmaceutical products, direct access to German pharmacies and full control of its value chain, as well as a stronger market presence with higher gross margins.
Gowling WLG advised Khiron with respect to this acquisition with a team that included Peter Simeon, Jacob Cawker and Ashley Andaya (corporate/M&A) and Paul Carenza (tax).

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.